- Glenmark has demonstrated a robust value growth of 9.9% in its dermatology portfolio for MAT medical audit Dec 2023, with its market share in the Indian dermatology segment reaching 7.49%
Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has been ranked number 1 in dermatologistsā prescriptions in the protective emollients category and for prescribing derma therapy. This is based on the IQVIA medical audit for MAT Dec 2023 (as per Projected Prescriptions) in India. Projected prescriptions figures are for the period from Jan 2023 to Dec 2023.Ā
Key products in Glenmarkās dermatology portfolio including EpisoftĀ®, Candid Dusting PowderĀ®, MomateĀ®, Canditral SBĀ®, La ShieldĀ®, ScalpeĀ®+, TacrozĀ® ointment, etc. have made significant strides in providing effective solutions for multiple dermatological conditions. The Companyās flagship brand CandidĀ® Powder delivered revenue growth of 20% for Q3 FY24. La ShieldĀ® portfolio delivered YoY revenue growth of 20%, while ScalpeĀ®+ portfolio witnessed YoY revenue growth of 12.2% in Q3 FY24.Ā
Mr. Alok Malik, President and Business Head ā India Formulations at Glenmark Pharmaceuticals Ltd, said, āWe are very excited to be ranked number 1 by prescription in the dermatology therapy as per IQVIA. Our strategic focus and expertise in dermatology reflect our commitment to advancing dermatological care and addressing a broad spectrum of skin health needs of patients in India. Leveraging a robust derma portfolio that spans a wide array of treatments, Glenmark is at the forefront of addressing both common and complex skin conditions.ā
Glenmark continues to outperform the market in the Dermatology segment. In the market analysis ending December 2023, the dermatology sector in Indian Pharmaceutical Market (IPM) grew 6.2% on a moving annual total (MAT) basis. GPL outperformed the overall market with a dermatology value growth of 9.9%. With a market share of 7.49% in the dermatology sector as per MAT Dec 2023.Ā
